MHRA Supports Avelumab With Axtinib for Advanced Renal Cancer

The MHRA’s Early Access to Medicines Scheme (EAMS) has issued a positive opinion for Merck’s Bavencio (avelumab) in combination with Inlyta (axitinib) as a first-line treatment for advanced renal cancer.

The two drugs are administered intravenously in an 800-milligram dose over 60 minutes every two weeks, with axitinib 5 mg taken orally twice daily with or without food.

The early access scheme provides earlier availability of promising new unlicensed medicines to UK patients with a high unmet clinical need.